# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...
Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury...
First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered...
-SEC Filing